The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized. The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized. Regulation and Deregulation of Industry, Psychedelic and Hallucinogenic Drugs, Ethics and Official Misconduct, Therapy and Rehabilitation, Veterans, Clinical Trials, Mental Health and Disorders, Psychiatry and Psychiatrists, Post-Traumatic Stress Disorder, Research, Drugs (Pharmaceuticals), Food and Drug Administration, Institute for Clinical and Economic Review, Lykos Therapeutics, Multidisciplinary Assn for Psychedelic Studies, Psymposia NYT > Science
How an Activist Group Helped Torpedo MDMA Therapy
